BeOne Medicines Ltd. furnished additional 2025 financial details tied to its STAR Market annual report, reconciling PRC GAAP disclosures to U.S. GAAP. Revenue for the year ended December 31, 2025 was $5,343,033 thousand, up from $3,810,241 thousand in 2024, with China contributing $1,679,531 thousand and ex-China $3,663,502 thousand.
The gross profit margin ratio was 66.6% in China and 97.0% ex-China for 2025. Total research and development expenses reached $2,145,868 thousand in 2025 versus $1,953,295 thousand in 2024, driven by key programs such as BRUKINSA, TEVIMBRA, sonrotoclax, BGB-16673 and other projects. The company also reported 6,268,800 vials of key products produced or purchased in 2025, with 5,996,100 vials sold and 2,912,600 vials in stock as of year-end.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry reported a series of routine equity transactions. He exercised options to acquire 4,433 Ordinary Shares at exercise prices of 14.96, 16.41, and 12.23 per share, which converted into 341 American Depositary Shares (ADSs). Each ADS represents 13 Ordinary Shares. He then sold 341 ADSs at 300.00 per ADS in an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 318,370 Ordinary Shares, indicating he retains a substantial equity position in the company.
OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.
OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.
Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.
Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.
BeOne Medicines Ltd. reported that President and Global Head of R&D Wang Lai received equity compensation in the form of performance share units on ordinary shares. The grants cover 112,606 shares vesting in 2027 and 55,029 shares vesting in 2028, subject to continued service and possible accelerated vesting upon certain termination events. After these awards, Wang directly holds 1,619,059 ordinary shares.
He also has indirect exposure to 601,965 ordinary shares held by Wang Holdings LLC, for which he disclaims beneficial ownership, and an indirect economic interest in RMB Shares acquired through an employee participation plan, over which he has no voting or dispositive power.
BeOne Medicines Ltd. reported that President and Global Head of R&D Wang Lai received equity compensation in the form of performance share units on ordinary shares. The grants cover 112,606 shares vesting in 2027 and 55,029 shares vesting in 2028, subject to continued service and possible accelerated vesting upon certain termination events. After these awards, Wang directly holds 1,619,059 ordinary shares.
He also has indirect exposure to 601,965 ordinary shares held by Wang Holdings LLC, for which he disclaims beneficial ownership, and an indirect economic interest in RMB Shares acquired through an employee participation plan, over which he has no voting or dispositive power.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported equity awards and updated share holdings. He received two grants classified as acquisitions of ordinary shares, covering 168,922 and 78,624 shares tied to performance share units. These earned units will vest in 2027 and 2028 if he continues serving the company, with unvested amounts eligible for accelerated vesting upon certain termination events. Following these awards, he directly holds 1,216,524 ordinary shares, 12,365 American Depositary Shares (ADSs) directly, and 4,000 ADSs indirectly through his wife. Each ADS represents 13 ordinary shares.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported equity awards and updated share holdings. He received two grants classified as acquisitions of ordinary shares, covering 168,922 and 78,624 shares tied to performance share units. These earned units will vest in 2027 and 2028 if he continues serving the company, with unvested amounts eligible for accelerated vesting upon certain termination events. Following these awards, he directly holds 1,216,524 ordinary shares, 12,365 American Depositary Shares (ADSs) directly, and 4,000 ADSs indirectly through his wife. Each ADS represents 13 ordinary shares.
BeOne Medicines Ltd. reported that Chief Financial Officer Aaron Rosenberg received equity compensation in the form of ordinary shares linked to performance share units. On March 6, 2026, he was granted 79,014 ordinary shares underlying earned performance share units that are scheduled to vest in 2027, and an additional 40,573 ordinary shares underlying earned performance share units scheduled to vest in 2028.
All of these earned performance share units will vest only if Rosenberg continues to provide service to the company through the respective vesting dates, with unvested awards eligible for accelerated vesting upon certain termination events. Following these awards, his direct ownership increased to 334,919 ordinary shares, reflecting a compensation-related acquisition rather than an open-market purchase.
BeOne Medicines Ltd. reported that Chief Financial Officer Aaron Rosenberg received equity compensation in the form of ordinary shares linked to performance share units. On March 6, 2026, he was granted 79,014 ordinary shares underlying earned performance share units that are scheduled to vest in 2027, and an additional 40,573 ordinary shares underlying earned performance share units scheduled to vest in 2028.
All of these earned performance share units will vest only if Rosenberg continues to provide service to the company through the respective vesting dates, with unvested awards eligible for accelerated vesting upon certain termination events. Following these awards, his direct ownership increased to 334,919 ordinary shares, reflecting a compensation-related acquisition rather than an open-market purchase.
BeOne Medicines Ltd. reports a strong 2025 with rapid growth and first-time profitability driven by its global oncology franchise. The company generated approximately $5.3 billion in total global revenue in 2025, up about 40.2% year over year, and produced net income of $286.9 million.
Operations generated $1.1 billion of net cash from operating activities and free cash flow of $941.7 million, supporting a year-end balance of $4.5 billion in cash and cash equivalents and $1.0 billion of debt. Product revenue grew 39.8% from 2024.
Growth is led by oncology blockbusters BRUKINSA, a BTK inhibitor with about $3.9 billion in 2025 sales and approvals in over 75 markets, and PD‑1 antibody TEVIMBRA, which is approved in more than 50 markets and broadly listed on China’s NRDL. The company is building a “foundational” chronic lymphocytic leukemia franchise around BRUKINSA, BCL2 inhibitor sonrotoclax, and BTK degrader BGB‑16673, while advancing a deep solid-tumor pipeline and over 70 preclinical programs.
BeOne Medicines Ltd. reports a strong 2025 with rapid growth and first-time profitability driven by its global oncology franchise. The company generated approximately $5.3 billion in total global revenue in 2025, up about 40.2% year over year, and produced net income of $286.9 million.
Operations generated $1.1 billion of net cash from operating activities and free cash flow of $941.7 million, supporting a year-end balance of $4.5 billion in cash and cash equivalents and $1.0 billion of debt. Product revenue grew 39.8% from 2024.
Growth is led by oncology blockbusters BRUKINSA, a BTK inhibitor with about $3.9 billion in 2025 sales and approvals in over 75 markets, and PD‑1 antibody TEVIMBRA, which is approved in more than 50 markets and broadly listed on China’s NRDL. The company is building a “foundational” chronic lymphocytic leukemia franchise around BRUKINSA, BCL2 inhibitor sonrotoclax, and BTK degrader BGB‑16673, while advancing a deep solid-tumor pipeline and over 70 preclinical programs.
BeOne Medicines delivered a strong 2025, with total revenue rising 40% to $5.34 billion and fourth-quarter revenue up 33% to $1.50 billion. Product revenue made up 99% of the total.
Flagship BTK inhibitor BRUKINSA generated $3.9 billion in 2025 sales, up 49%, including $2.8 billion in the U.S. TEVIMBRA added $737 million, up 19%, while Amgen in-licensed products contributed $486 million, up 33%.
GAAP net income improved to $286.9 million from a $644.8 million loss, and free cash flow reached $941.7 million. For 2026, BeOne guides total revenue to $6.2–$6.4 billion, GAAP operating income of $700–$800 million, and non-GAAP operating income of $1.4–$1.5 billion, with gross margin expected in the high-80% range.
BeOne Medicines delivered a strong 2025, with total revenue rising 40% to $5.34 billion and fourth-quarter revenue up 33% to $1.50 billion. Product revenue made up 99% of the total.
Flagship BTK inhibitor BRUKINSA generated $3.9 billion in 2025 sales, up 49%, including $2.8 billion in the U.S. TEVIMBRA added $737 million, up 19%, while Amgen in-licensed products contributed $486 million, up 33%.
GAAP net income improved to $286.9 million from a $644.8 million loss, and free cash flow reached $941.7 million. For 2026, BeOne guides total revenue to $6.2–$6.4 billion, GAAP operating income of $700–$800 million, and non-GAAP operating income of $1.4–$1.5 billion, with gross margin expected in the high-80% range.